Abstract
New regulatory changes were introduced in January further restricting the prescription of valproate medicines in patients under 55 years of age due to the significant reproductive risks. This article discusses these changes as well as the other issues to consider to ensure valproate prescribing is as safe as possible, including monitoring for adverse effects and avoiding interactions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
